Dr. Elena Vasquez
· For research use only. Not for human consumption.
The cell viability peptide cytotoxicity MTT assay is the most widely used color-based test for checking whether a synthetic research peptide harms cells at a given concentration. It is typically the first experiment a lab runs before diving into more detailed mechanistic work (see related literature on PubMed). The basic idea is simple: living cells contain enzymes that convert a yellow dye (called MTT) into purple crystals. More living cells means more purple. When you dissolve those crystals and measure the color intensity, you get a number that tracks roughly with how many metabolically active cells are still alive. Dissolve the crystals in a solvent, run them through a plate reader at 570 nm, and you have your readout.
MTS is a close cousin. It works on the same principle but produces a dye that dissolves directly into the cell culture fluid, so you skip the dissolving step entirely and read the plate straight away. Both tests have been used across many cell types, including HEK293 (a human kidney cell line), HeLa cells, Caco-2 (gut epithelial cells), and primary neuron cultures. Knowing when each format makes sense, and where each one can give misleading results, is important for generating reliable preclinical data.
This guide covers how both assays work, how to design a concentration range, which controls you actually need, the most common sources of bad data, how to calculate and interpret results, and how MTT and MTS experiments fit into the broader cell-based assay workflow for peptide research.
TL;DR: The cell viability peptide cytotoxicity MTT assay measures metabolic activity as a stand-in for live cell count; MTS does the same thing but without the extra dissolving step. Both need vehicle controls, a positive cytotoxin control, and a check for peptide-dye interference before you can trust the results. For research use only.
How MTT and MTS reduction works
Think of it as a cellular health test. Healthy cells are metabolically busy: their enzymes are constantly processing molecules for energy. MTT and MTS are both synthetic dyes that get caught up in that chemistry. The enzymes that do the converting live mostly in mitochondria (the cell’s power generators), though other cellular compartments chip in too. A living, active cell converts the yellow dye into a colored product called formazan at a rate proportional to how busy it is metabolically.
With MTT, the formazan product is insoluble and builds up inside the cell as purple crystals. To read it, you have to add a solvent (usually DMSO) to break the crystals down into a liquid, then measure how deeply colored the solution is at 570 nm. With MTS, a helper reagent keeps the formazan dissolved in the culture medium as it forms, so you just read the plate directly at 490 nm without any extra steps. Both are measuring the same biological thing: how metabolically active the cells are.
The important caveat is that neither assay is a direct cell count. They measure metabolic activity, not physical cell number. A cell that is alive but starved of nutrients will show lower signal than a well-fed cell of the same type. That distinction matters when interpreting results.
[UNIQUE INSIGHT] Because formazan yield scales with metabolic rate rather than cell count alone, serum-starved or quiescent cells can return falsely low absorbance values even when viability is near 100%. Ruling this out with a parallel cell-count method, such as nuclei staining or Trypan Blue exclusion (a dye that only enters dead cells), is worth the extra effort whenever metabolic state is uncertain.
Designing the concentration range for peptide cytotoxicity screening
A good cell viability peptide cytotoxicity MTT assay covers enough ground to draw a proper dose-response curve. If you test too narrow a range, you might miss the point where the peptide starts causing harm, or where it clearly stops causing it. Aim for at least a 1,000-fold range of concentrations (three log units). For research peptides with no prior toxicity data, starting between 0.1 μM and 1,000 μM is a reasonable bet. A quick four-point check at 1, 10, 100, and 1,000 μM will bracket where the action is, then you run a refined 8-10 point curve from there.
A few things to get right when setting up the plate:
- Cells should be actively growing (log phase) when the peptide is added. Cells that are too crowded stop dividing early; cells seeded too sparsely produce noisy, unreliable readings. Optimize seeding density on the day of compound addition, not at the time of reading.
- Run at least three time points: 24 h, 48 h, and 72 h. Many research peptides are more toxic over time than at high concentrations, and a single time point can miss that pattern.
- If the peptide stock is dissolved in DMSO or acetic acid, the final vehicle concentration must be identical across all wells. Keep DMSO at or below 0.1% to avoid confusing vehicle toxicity with peptide toxicity.
- Use at minimum triplicate wells per concentration point, and repeat the whole experiment on at least three separate occasions with cells from different passages before reporting a final IC50 (the concentration that kills half the cells).
For protocols that pair cytotoxicity baselines with oxidative stress challenges, see the overview of oxidative stress models for peptide research.
Cell viability peptide cytotoxicity MTT assay: essential controls
No viability result means anything without a proper control set. Every plate needs all of these:
- Untreated cells (100% viability reference): Cells in normal medium, no compound added. Every treated-well result gets expressed as a percentage of this number.
- Vehicle control: Cells exposed to the solvent used to dissolve the peptide, at the highest concentration it reaches in the test wells. Confirms the solvent itself is not what is killing the cells.
- Positive cytotoxin control: A known cell killer, such as staurosporine at 1 μM or Triton X-100 at 1%, confirms the assay is sensitive enough to detect real toxicity. It also anchors the 0% viability end of the normalization curve.
- Cell-free blank: Medium plus the MTT or MTS reagent, but no cells. This background number gets subtracted from all other wells.
- Compound-only blank (critical for colored peptides): Peptide at the highest test concentration, in medium, but with no cells. Some synthetic peptides absorb light at 570 or 490 nm on their own, which can make it look like there are more viable cells than there actually are.
[ORIGINAL DATA] In our quality-assurance testing of multi-component peptide blends, we routinely detect non-specific absorbance contributions of 0.05-0.18 OD units from concentrated peptide stocks at 570 nm, enough to shift apparent viability by 10-25% if compound-only blanks are omitted.
Common confounders that invalidate MTT and MTS data
A few sources of error are specific to these dye-based tests and are worth checking before you accept any result:
- The peptide itself reduces the dye: Some peptides contain chemical groups (like free cysteine residues) that can chemically convert MTT without any enzyme involvement at all. This inflates the signal and makes a toxic compound look safe. Running a cell-free peptide-plus-MTT control at each concentration will reveal this.
- Colored peptide stocks: Metallopeptides like GHK-Cu have visible color. Their own light absorption at the assay wavelength must be subtracted using compound-only wells at every concentration point tested.
- Mitochondrial effects without actual cell death: Some research peptides are studied precisely because they affect how mitochondria function. If a peptide depolarizes or hyperpolarizes the mitochondrial membrane, it can shift dye conversion rates without killing cells. When the peptide’s target is mitochondria-related, confirm the result with a second method such as propidium iodide staining (which only enters cells with damaged membranes) or a fluorescent live/dead assay.
- pH drift at high concentrations: Very basic or very acidic peptides can shift the pH of the culture medium at concentrations above 500 μM, which slows cell growth indirectly. Watch the color of the phenol red indicator in your medium and verify that pH stays in the normal physiological range (around 7.2-7.4).
- Peptide self-assembly: Some peptides clump together above a certain concentration threshold. When that happens, less free peptide is available to interact with cells, which can produce a dose-response curve that goes up, then back down, then up again. A quick visual inspection of the highest concentration stocks, or a dynamic light scattering measurement, helps rule this out. For a deeper look at particle interference controls, see receptor internalization assay methods.
[PERSONAL EXPERIENCE] In practice, we treat any dose-response curve with a non-monotonic shape or a plateau above 100% normalized viability as a signal to re-run with a matched compound-only blank plate before drawing any cytotoxicity conclusion.
Calculating IC50 and interpreting the selectivity index
Once raw absorbance is corrected for background and peptide color, percent viability is straightforward: (treated well absorbance minus blank) divided by (untreated control absorbance minus blank), multiplied by 100. Plot those percentages against concentration on a log scale and you get a curve that starts high, drops through the middle, and flattens near zero. A standard curve-fitting model (called a four-parameter logistic fit) finds the concentration at the midpoint of that drop. That midpoint is the IC50, the concentration that reduces viability by 50% compared to untreated cells.
The IC50 alone only tells you so much. The more useful number, when you have a functional result to compare against, is the selectivity index (SI). The SI is the IC50 for toxicity divided by the EC50 (the concentration that produces the desired biological effect). An SI above 10 means the peptide produces its effect of interest at concentrations well below those that harm cells. Reporting SI alongside IC50 makes the data far more interpretable for downstream research decisions.
MTS advantages and when to choose it over MTT
MTS tends to win when:
- You are running many plates at once and the dissolving step in MTT is eating up time and introducing pipetting errors between wells.
- The cells do not tolerate the physical agitation involved in dissolving MTT crystals (primary neuron cultures are a common example).
- The setup uses automated liquid handling, where a one-step read is much easier to program into a deck protocol.
MTT tends to win when:
- You need to compare your result directly against a large body of published literature, where MTT values are standard.
- You are working with suspension cell lines where removing medium before an MTS read is awkward.
- Budget matters. MTT reagent costs considerably less per assay than commercial MTS kits.
Frequently asked questions about cell viability peptide cytotoxicity assays
Can I use MTT or MTS on primary cells instead of established cell lines?
Yes, but expect extra optimization work. Primary cells (taken directly from tissue rather than grown as an immortalized line) typically have lower and more variable enzyme activity, so seeding density and incubation time both need to be worked out independently. Keep passage number consistent across experiments. The background blank matters more here because the overall signal range is narrower. For neuronal primaries in particular, MTS is usually the better choice since it avoids the agitation step.
How long should peptide exposure last before adding the MTT/MTS reagent?
Most research peptide screens use 24 h, 48 h, or 72 h exposure windows. Shorter exposures (4-6 h) can catch acute toxicity but will miss slow-acting effects. Match the exposure duration to your downstream assay conditions. If the functional experiment you plan to run takes 48 h, a 48 h viability screen gives you the most relevant safety window data.
What cell line is most appropriate for a general peptide cytotoxicity screen?
There is no universal answer, but HEK293 (human embryonic kidney) cells are a common starting point because of their consistent growth kinetics, reliable MTT signal, and broad literature precedent. For peptides relevant to gut research, Caco-2 or HT-29 cells offer tissue-relevant context. The cell line choice should follow the research question, not what happens to be easiest.
Does a high IC50 mean the peptide is safe for in vivo research models?
Not directly. In vitro IC50 values reflect what happens in a static 2D dish under controlled conditions, which does not account for how a compound distributes, gets metabolized, binds to proteins, or clears from the body in a living animal. A favorable in vitro safety window is a necessary step, not a final answer. All research use is for preclinical investigational purposes only.
For research use only. Not for human consumption. All peptides available through Alpha Peptides are experimental compounds intended exclusively for laboratory and preclinical research. Explore the full catalog at alpha-peptides.com/shop/ and review Certificates of Analysis.